(NYSE: LLY) Eli Lilly & Co's forecast annual revenue growth rate of 14.61% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Eli Lilly & Co's revenue in 2025 is $59,419,800,000.On average, 31 Wall Street analysts forecast LLY's revenue for 2025 to be $60,720,107,944,596, with the lowest LLY revenue forecast at $57,422,609,400,180, and the highest LLY revenue forecast at $64,475,172,227,400. On average, 31 Wall Street analysts forecast LLY's revenue for 2026 to be $72,635,724,817,824, with the lowest LLY revenue forecast at $63,822,857,435,070, and the highest LLY revenue forecast at $81,913,721,009,022.
In 2027, LLY is forecast to generate $84,563,631,679,893 in revenue, with the lowest revenue forecast at $71,125,001,574,138 and the highest revenue forecast at $98,970,334,752,816.